In this trial arterial thromboembolic events were observed in 11% (11/ 100) of patients compared to 5.8% (6/ 104) in the chemotherapy control group.
Selles uuringus täheldati arteriaalseid trombemboolseid seisundeid 11% (11/ 100) patsientidest võrreldes 5, 8% - ga (6/ 104) kemoteraapia kontrollgrupis.